Recursion Pharmaceuticals Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 800

Employees

  • Stock Symbol
  • RXRX

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $4.56
  • (As of Friday Closing)

Recursion Pharmaceuticals General Information

Description

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Contact Information

Website
www.recursion.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 41 South Rio Grande Street
  • Salt Lake City, UT 84101
  • United States
+1 (385)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Artificial Intelligence & Machine Learning, Life Sciences, Oncology
Corporate Office
  • 41 South Rio Grande Street
  • Salt Lake City, UT 84101
  • United States
+1 (385)

Recursion Pharmaceuticals Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Recursion Pharmaceuticals Stock Performance

As of 16-May-2025, Recursion Pharmaceuticals’s stock price is $4.56. Its current market cap is $1.85B with 406M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.56 $4.25 $3.79 - $12.36 $1.85B 406M 24.1M -$1.77

Recursion Pharmaceuticals Financials Summary

As of 31-Mar-2025, Recursion Pharmaceuticals has a trailing 12-month revenue of $59.8M.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 1,640,673 2,304,259 1,792,670 1,059,019
Revenue 59,815 58,488 43,876 39,681
EBITDA (542,044) (441,874) (326,745) (233,919)
Net Income (574,775) (463,661) (328,066) (239,476)
Total Assets 1,305,234 1,448,598 653,699 701,288
Total Debt 92,910 108,492 50,672 51,005
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Recursion Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Recursion Pharmaceuticals‘s full profile, request access.

Request a free trial

Recursion Pharmaceuticals Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Recursion Pharmaceuticals‘s full profile, request access.

Request a free trial

Recursion Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating
Drug Discovery
Salt Lake City, UT
800 As of 2024

Nottingham, United Kingdom
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Recursion Pharmaceuticals Competitors (30)

One of Recursion Pharmaceuticals’s 30 competitors is Sygnature Discovery, a Private Equity-Backed company based in Nottingham, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom
Twist Bioscience Formerly VC-backed South San Francisco, CA
Affimed Formerly VC-backed Mannheim, Germany
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Verge Genomics Venture Capital-Backed South San Francisco, CA
You’re viewing 5 of 30 competitors. Get the full list »

Recursion Pharmaceuticals Patents

  • 184

    Total Documents Applications and Grants

  • Total Patents Families

  • 107

    Granted

  • 62

    Pending

  • Expiring in next 12 mo

Recursion Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12300360-B2 Preemptible-based scaffold hopping Active 15-May-2024
US-12119090-B1 Utilizing masked autoencoder generative models to extract microscopy representation autoencoder embeddings Active 19-Dec-2023
US-12119091-B1 Utilizing masked autoencoder generative models to extract microscopy representation autoencoder embeddings Active 19-Dec-2023
US-20250157569-A1 Utilizing compound-protein machine learning representations to generate bioactivity predictions Pending 09-Nov-2023
US-20250157595-A1 Utilizing compound-protein machine learning representations to generate bioactivity predictions Pending 09-Nov-2023 G16C20/70
To view Recursion Pharmaceuticals’s complete patent history, request access »

Recursion Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Recursion Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Recursion Pharmaceuticals‘s full profile, request access.

Request a free trial

Recursion Pharmaceuticals Investments & Acquisitions (5)

Recursion Pharmaceuticals’s most recent deal was a Merger/Acquisition with Exscientia for . The deal was made on 20-Nov-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Exscientia 20-Nov-2024 Merger/Acquisition Drug Discovery
Cyclica 25-May-2023 Merger/Acquisition Discovery Tools (Healthcare)
Valence Labs 16-May-2023 Merger/Acquisition Drug Discovery
Enveda 22-Jun-2021 Early Stage VC Drug Discovery
Vium 28-Jul-2020 Merger/Acquisition Discovery Tools (Healthcare)
To view Recursion Pharmaceuticals’s complete investments and acquisitions history, request access »

Recursion Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated March, 28, 2025

17.4 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,631

Rank

Percentile

Pharmaceuticals

Industry

of 843

Rank

Percentile

Biotechnology

Subindustry

of 365

Rank

Percentile

To view Recursion Pharmaceuticals’s complete esg history, request access »

Recursion Pharmaceuticals Affiliates

Subsidiaries (4)

Name Industry Location Year Founded
Valence Labs Montreal, Canada 2018
Cyclica Toronto, Canada 2013
Vium San Mateo, CA 2013
Exscientia Oxford, United Kingdom 2012

Recursion Pharmaceuticals FAQs

  • When was Recursion Pharmaceuticals founded?

    Recursion Pharmaceuticals was founded in 2013.

  • Where is Recursion Pharmaceuticals headquartered?

    Recursion Pharmaceuticals is headquartered in Salt Lake City, UT.

  • What is the size of Recursion Pharmaceuticals?

    Recursion Pharmaceuticals has 800 total employees.

  • What industry is Recursion Pharmaceuticals in?

    Recursion Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Recursion Pharmaceuticals a private or public company?

    Recursion Pharmaceuticals is a Public company.

  • What is Recursion Pharmaceuticals’s stock symbol?

    The ticker symbol for Recursion Pharmaceuticals is RXRX.

  • What is the current stock price of Recursion Pharmaceuticals?

    As of 16-May-2025 the stock price of Recursion Pharmaceuticals is $4.56.

  • What is the current market cap of Recursion Pharmaceuticals?

    The current market capitalization of Recursion Pharmaceuticals is $1.85B.

  • What is Recursion Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Recursion Pharmaceuticals is $59.8M.

  • Who are Recursion Pharmaceuticals’s competitors?

    Sygnature Discovery, Twist Bioscience, Affimed, Inovio Pharmaceuticals, and Verge Genomics are some of the 30 competitors of Recursion Pharmaceuticals.

  • What is Recursion Pharmaceuticals’s annual earnings per share (EPS)?

    Recursion Pharmaceuticals’s EPS for 12 months was -$1.77.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »